Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000919574-26-002927
Filing Date
2026-05-13
Accepted
2026-05-13 09:14:01
Documents
2
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10734
2 JOINT FILING STATEMENT d12144695_ex99-1.htm EX-99.1 3573
  Complete submission text file 0000919574-26-002927.txt   16092
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Subject) CIK: 0001419041 (see all company filings)

EIN.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-89959 | Film No.: 26971245
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 200 CLARENDON STREET, 52ND FLOOR BOSTON MA 02116
Business Address 200 CLARENDON STREET, 52ND FLOOR BOSTON MA 02116 617-867-2800
Adage Capital Management, L.P. (Filed by) CIK: 0001535978 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G